First Quarter 2023 Reflected Continued Strong Underlying Performance Across Key Growth Drivers, Particularly in Oncology and Vaccines
Total Worldwide Sales Were $14.5 Billion, a Decrease of 9%. | April 27, 2023
Acceptance based on results from the Phase 3 KEYNOTE-859 trial, which showed significant overall survival benefit in these patients with HER2-negative disease, regardless of PD-L1 expression
. | April 13, 2023
By Stephen Nakrosis Merck & Co. said Monday it would pause enrollment in Phase 3 clinical studies evaluating oral islatravir for pre-exposure prophylaxis in people at high risk of HIV-1. | December 7, 2021